Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.69 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.66 |
| ▸ | TNKS | O95271 | 1/20 | 0.58 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.58 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.58 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.58 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631297 | 0.91 | PARP1 (0.67) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630128 | 0.82 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL631380 | 0.80 | PARP1 (0.72) | PARP1PARP2 | |
| SCHEMBL631124 | 0.80 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL631393 | 0.79 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL629937 | 0.79 | PARP1 (0.92) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL631085 | 0.79 | PARP1 (0.77) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630095 | 0.78 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL630603 | 0.78 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630394 | 0.78 | PARP1 (1.00) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869011-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | claimed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | claimed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | claimed |
| EP-2338487-B1 | Combination therapy with PARP inhibitors | ABBOTT LAB (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2420234-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION AS PARP INHIBITORS FOR USE IN TREATING CANCER | ABBOTT LAB (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2420499-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION AS POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-1869011-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2420499-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as potent PARP inhibitors | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420234-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as PARP inhibitors for use in treating cancer | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2338487-A1 | Combination therapy with PARP inhibitors | Abbott Laboratories (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-2329818-A1 | Combination therapy with PARP inhibitors | Abbott Laboratories (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1869011-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110816-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | PARP1 1/4885PARP2 2/4885TNKS 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.